The updated investor presentation outlines Actinogen’s key investment highlights, clinical progress and outlook and will be used to update shareholders, investors and brokers as part of a non-deal roadshow across Australia.
We are pleased to announce the publication of a research and analyst report on the Company, by Edison.
Dr Bill Ketelbey, CEO, provides an overview of Actinogen, their lead compound Xanamem that inhibits excess cortisol production in the brain and discusses how chronically raised cortisol is associated with cognitive impairment and the development and progression of Alzheimer’s disease. Find out the excellent progress made, what the next steps are and the way forward in a number of new indications.
Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."